Nuclera Nucleics

Nuclera Nucleics

Making biology accessible by providing researchers a desktop bioprinter capable to produce genes and proteins in one day. Learn more

Financials

Estimates*

Edit
Revenues, earnings & profits over time
GBP20212022
Revenues<1m<1m
% growth-9872 %
EBITDA(3.0m)(4.9m)
% EBITDA margin(179534 %)(2961 %)
Profit(4.7m)(5.8m)
% profit margin(286316 %)(3498 %)
  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

£100k

Grant
N/A

£25.0k

Grant
N/A

£203k

Grant
N/A

$10.0m

Late VC
*

$42.5m

Series B
*

$15.5m

Series B
*

£1.1m

Grant
Total Funding€63.5m

Recent News about Nuclera Nucleics

Edit
More about Nuclera Nucleicsinfo icon
Edit

Nuclera is a biotechnology company specializing in on-demand gene to protein synthesis, enabling scientists to create, build, and engineer biology directly in their own laboratories. The company serves researchers and scientists in the field of synthetic biology, providing high-quality genes and proteins with a focus on speed, flexibility, and accuracy. Nuclera operates in the synthetic biology market, leveraging a biologically inspired platform that allows for the rapid construction of genes, often within a day. The business model revolves around selling its proprietary technology and related services to laboratories and research institutions, generating revenue through the sale of its synthesis platform and consumables. By making gene and protein writing accessible and customizable, Nuclera aims to revolutionize the way biological research is conducted.

Keywords: gene synthesis, protein synthesis, synthetic biology, biotechnology, laboratory tools, research, high accuracy, customization, rapid construction, benchtop technology.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.